<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01659255</url>
  </required_header>
  <id_info>
    <org_study_id>ONO-4059POE001</org_study_id>
    <secondary_id>2011-005033-39</secondary_id>
    <nct_id>NCT01659255</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Tolerability of Tirabrutinib (ONO/GS-4059) Given as Monotherapy in Participants With Relapsed/Refractory NHL and CLL</brief_title>
  <official_title>An Open-label, Multi-Center, Non-Randomised Phase I Dose-Escalation Study to Investigate the Safety and Tolerability of ONO-4059 (ONO/GS-4059) Given as Monotherapy in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma (NHL) and Relapsed/Refractory Chronic Lymphocytic Leukaemia (CLL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ono Pharmaceutical Co. Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to evaluate the safety and tolerability of tirabrutinib&#xD;
      (formerly ONO/GS-4059) given as monotherapy to participants with relapsed/refractory&#xD;
      non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 17, 2012</start_date>
  <completion_date type="Actual">January 11, 2016</completion_date>
  <primary_completion_date type="Actual">February 23, 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Experiencing Dose-Limiting Toxicities</measure>
    <time_frame>Day 1 through Day 28</time_frame>
    <description>Dose Limiting Toxicities (DLT) were defined as follows:&#xD;
All Common Terminology Criteria (CTC) Grade 4 tirabrutinib related adverse events&#xD;
All CTC Grade 3 tirabrutinib related adverse events, with the exception of the following:&#xD;
CTC Grade 3 lymphocytosis considered an expected outcome of therapy&#xD;
Any toxicity which in the opinion of the Investigator is attributed to a participant's underlying disease was not considered a DLT.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>Up to Cycle 37 (28 days for each cycle) plus 6-month intervals thereafter until disease progression (maximum: up to 39 months)</time_frame>
    <description>Overall response rate (ORR) was defined as the percentage of participants who achieve a best overall response of complete remission (CR, unconfirmed complete response (CRu), complete response with incomplete marrow recovery (CRi)) or partial remission (PR, nodal PR) during study as assessed by the investigator.&#xD;
ORR assessment was defined per following standardized criteria:&#xD;
NHL: Cheson, 1999&#xD;
CLL: International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) Parameter: Cmax of Tirabrutinib</measure>
    <time_frame>Pre-dose, then 30 minutes, 1, 2, 3, 4, 6, 8, 12 hours post-dose at Cycle 1, Day 28</time_frame>
    <description>Cmax is defined as the maximum concentration of drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: AUCtau of Tirabrutinib</measure>
    <time_frame>Pre-dose, then 30 minutes, 1, 2, 3, 4, 6, 8, 12 hours post-dose at Cycle 1, Day 28</time_frame>
    <description>AUCtau is defined as concentration of drug over dosing interval.</description>
  </secondary_outcome>
  <number_of_arms>17</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Non Hodgkins Lymphoma</condition>
  <condition>Chronic Lymphocytic Leukaemia</condition>
  <arm_group>
    <arm_group_label>Tirabrutinib 20 mg Once Daily (CLL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with relapsed/refractory chronic lymphocytic leukaemia (CLL) received tirabrutinib 20 mg once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tirabrutinib 40 mg Once Daily (CLL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with relapsed/refractory CLL received tirabrutinib 40 mg once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tirabrutinib 80 mg Once Daily (CLL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with relapsed/refractory CLL received tirabrutinib 80 mg once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tirabrutinib 160 mg Once Daily (CLL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with relapsed/refractory CLL received tirabrutinib 160 mg once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tirabrutinib 320 mg Once Daily (CLL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with relapsed/refractory CLL received tirabrutinib 320 mg once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tirabrutinib 400 mg Once Daily (CLL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with relapsed/refractory CLL received tirabrutinib 400 mg once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tirabrutinib 500 mg Once Daily (CLL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with relapsed/refractory CLL received tirabrutinib 500 mg once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tirabrutinib 600 mg Once Daily (CLL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with relapsed/refractory CLL received tirabrutinib 600 mg once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tirabrutinib 300 mg Twice Daily (CLL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with relapsed/refractory CLL received tirabrutinib 300 mg twice daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tirabrutinib 20 mg Once Daily (NHL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with relapsed/refractory non-Hodgkin's lymphoma (NHL) received tirabrutinib 20 mg once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tirabrutinib 40 mg Once Daily (NHL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with relapsed/refractory NHL received tirabrutinib 40 mg once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tirabrutinib 80 mg Once Daily (NHL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with relapsed/refractory NHL received tirabrutinib 80 mg once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tirabrutinib 160 mg Once Daily (NHL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with relapsed/refractory NHL received tirabrutinib 160 mg once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tirabrutinib 320 mg Once Daily (NHL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with relapsed/refractory NHL received tirabrutinib 320 mg once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tirabrutinib 480 mg Once Daily (NHL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with relapsed/refractory NHL received tirabrutinib 480 mg once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tirabrutinib 600 mg Once Daily (NHL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with relapsed/refractory NHL received tirabrutinib 600 mg once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tirabrutinib 240 mg Twice Daily (NHL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with relapsed/refractory NHL received tirabrutinib 240 mg twice daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tirabrutinib</intervention_name>
    <description>Capsules administered orally</description>
    <arm_group_label>Tirabrutinib 160 mg Once Daily (CLL)</arm_group_label>
    <arm_group_label>Tirabrutinib 160 mg Once Daily (NHL)</arm_group_label>
    <arm_group_label>Tirabrutinib 20 mg Once Daily (CLL)</arm_group_label>
    <arm_group_label>Tirabrutinib 20 mg Once Daily (NHL)</arm_group_label>
    <arm_group_label>Tirabrutinib 240 mg Twice Daily (NHL)</arm_group_label>
    <arm_group_label>Tirabrutinib 300 mg Twice Daily (CLL)</arm_group_label>
    <arm_group_label>Tirabrutinib 320 mg Once Daily (CLL)</arm_group_label>
    <arm_group_label>Tirabrutinib 320 mg Once Daily (NHL)</arm_group_label>
    <arm_group_label>Tirabrutinib 40 mg Once Daily (CLL)</arm_group_label>
    <arm_group_label>Tirabrutinib 40 mg Once Daily (NHL)</arm_group_label>
    <arm_group_label>Tirabrutinib 400 mg Once Daily (CLL)</arm_group_label>
    <arm_group_label>Tirabrutinib 480 mg Once Daily (NHL)</arm_group_label>
    <arm_group_label>Tirabrutinib 500 mg Once Daily (CLL)</arm_group_label>
    <arm_group_label>Tirabrutinib 600 mg Once Daily (CLL)</arm_group_label>
    <arm_group_label>Tirabrutinib 600 mg Once Daily (NHL)</arm_group_label>
    <arm_group_label>Tirabrutinib 80 mg Once Daily (CLL)</arm_group_label>
    <arm_group_label>Tirabrutinib 80 mg Once Daily (NHL)</arm_group_label>
    <other_name>ONO/GS-4059</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Males or females with a confirmed diagnosis of and documented history of relapsed or&#xD;
             refractory malignant disease (B-cell lymphoma and/or CLL) for which no therapy of&#xD;
             curative or high priority exists and for whom treatment with a Btk inhibitor may be&#xD;
             deemed appropriate.&#xD;
&#xD;
          2. Age ≥ 18 years.&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Central nervous system (CNS) lymphoma.&#xD;
&#xD;
          2. Women who are pregnant or lactating.&#xD;
&#xD;
        Note: Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHRU - Hopital Claude HURIEZ</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier Lyon Sud</name>
      <address>
        <city>Lyon</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU St Eloi</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Wales</name>
      <address>
        <city>Cardiff</city>
        <zip>CF14 4XW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leicester Royal Infirmary</name>
      <address>
        <city>Leicester</city>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Derriford Hospital</name>
      <address>
        <city>Plymouth</city>
        <zip>PL6 8DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Walter HS, Salles GA, Dyer MJ. New Agents to Treat Chronic Lymphocytic Leukemia. N Engl J Med. 2016 Jun 2;374(22):2185-6. doi: 10.1056/NEJMc1602674.</citation>
    <PMID>27248633</PMID>
  </results_reference>
  <results_reference>
    <citation>Walter HS, Rule SA, Dyer MJ, Karlin L, Jones C, Cazin B, Quittet P, Shah N, Hutchinson CV, Honda H, Duffy K, Birkett J, Jamieson V, Courtenay-Luck N, Yoshizawa T, Sharpe J, Ohno T, Abe S, Nishimura A, Cartron G, Morschhauser F, Fegan C, Salles G. A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies. Blood. 2016 Jan 28;127(4):411-9. doi: 10.1182/blood-2015-08-664086. Epub 2015 Nov 5.</citation>
    <PMID>26542378</PMID>
  </results_reference>
  <results_reference>
    <citation>Fegan, C, Bagshawe J, Salles G, et al. The Bruton's tyrosine kinase (BTK) inhibitor ONO-4059: promising single agent activity and well tolerated in patients with high risk chronic lymphocytic leukaemia (CLL). Paper presented at: 56th American Society of Hematology Annual Meeting and Exposition; December 6-9, 2014; San Franscisco, CA.</citation>
  </results_reference>
  <results_reference>
    <citation>Morschhauser F, Terriou L, Dyer M, et al. The Bruton's tyrosine kinase (BTK) inhibitor ONO-4059: promising single agent activity in patients with relapsed and refractory NHL. Haematologica. 2014 Jun; 99: 150.</citation>
  </results_reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>July 6, 2012</study_first_submitted>
  <study_first_submitted_qc>August 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2012</study_first_posted>
  <results_first_submitted>January 6, 2021</results_first_submitted>
  <results_first_submitted_qc>January 6, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">January 28, 2021</results_first_posted>
  <last_update_submitted>February 22, 2021</last_update_submitted>
  <last_update_submitted_qc>February 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled at study sites in Europe. The first participant was screened on 17 August 2012. The last study visit occurred on 11 January 2016.</recruitment_details>
      <pre_assignment_details>102 participants were screened.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Tirabrutinib 20 mg Once Daily (CLL)</title>
          <description>Participants with relapsed/refractory chronic lymphocytic leukaemia (CLL) received tirabrutinib 20 mg once daily.</description>
        </group>
        <group group_id="P2">
          <title>Tirabrutinib 40 mg Once Daily (CLL)</title>
          <description>Participants with relapsed/refractory CLL received tirabrutinib 40 mg once daily.</description>
        </group>
        <group group_id="P3">
          <title>Tirabrutinib 80 mg Once Daily (CLL)</title>
          <description>Participants with relapsed/refractory CLL received tirabrutinib 80 mg once daily.</description>
        </group>
        <group group_id="P4">
          <title>Tirabrutinib 160 mg Once Daily (CLL)</title>
          <description>Participants with relapsed/refractory CLL received tirabrutinib 160 mg once daily.</description>
        </group>
        <group group_id="P5">
          <title>Tirabrutinib 320 mg Once Daily (CLL)</title>
          <description>Participants with relapsed/refractory CLL received tirabrutinib 320 mg once daily.</description>
        </group>
        <group group_id="P6">
          <title>Tirabrutinib 400 mg Once Daily (CLL)</title>
          <description>Participants with relapsed/refractory CLL received tirabrutinib 400 mg once daily.</description>
        </group>
        <group group_id="P7">
          <title>Tirabrutinib 500 mg Once Daily (CLL)</title>
          <description>Participants with relapsed/refractory CLL received tirabrutinib 500 mg once daily.</description>
        </group>
        <group group_id="P8">
          <title>Tirabrutinib 600 mg Once Daily (CLL)</title>
          <description>Participants with relapsed/refractory CLL received tirabrutinib 600 mg once daily.</description>
        </group>
        <group group_id="P9">
          <title>Tirabrutinib 300 mg Twice Daily (CLL)</title>
          <description>Participants with relapsed/refractory CLL received tirabrutinib 300 mg twice daily.</description>
        </group>
        <group group_id="P10">
          <title>Tirabrutinib 20 mg Once Daily (NHL)</title>
          <description>Participants with relapsed/refractory non-Hodgkin's lymphoma (NHL) received tirabrutinib 20 mg once daily.</description>
        </group>
        <group group_id="P11">
          <title>Tirabrutinib 40 mg Once Daily (NHL)</title>
          <description>Participants with relapsed/refractory NHL received tirabrutinib 40 mg once daily.</description>
        </group>
        <group group_id="P12">
          <title>Tirabrutinib 80 mg Once Daily (NHL)</title>
          <description>Participants with relapsed/refractory NHL received tirabrutinib 80 mg once daily.</description>
        </group>
        <group group_id="P13">
          <title>Tirabrutinib 160 mg Once Daily (NHL)</title>
          <description>Participants with relapsed/refractory NHL received tirabrutinib 160 mg once daily.</description>
        </group>
        <group group_id="P14">
          <title>Tirabrutinib 320 mg Once Daily (NHL)</title>
          <description>Participants with relapsed/refractory NHL received tirabrutinib 320 mg once daily.</description>
        </group>
        <group group_id="P15">
          <title>Tirabrutinib 480 mg Once Daily (NHL)</title>
          <description>Participants with relapsed/refractory NHL received tirabrutinib 480 mg once daily.</description>
        </group>
        <group group_id="P16">
          <title>Tirabrutinib 600 mg Once Daily (NHL)</title>
          <description>Participants with relapsed/refractory NHL received tirabrutinib 600 mg once daily.</description>
        </group>
        <group group_id="P17">
          <title>Tirabrutinib 240 mg Twice Daily (NHL)</title>
          <description>Participants with relapsed/refractory NHL received tirabrutinib 240 mg twice daily.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="3"/>
                <participants group_id="P11" count="3"/>
                <participants group_id="P12" count="5"/>
                <participants group_id="P13" count="8"/>
                <participants group_id="P14" count="21"/>
                <participants group_id="P15" count="10"/>
                <participants group_id="P16" count="9"/>
                <participants group_id="P17" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="3"/>
                <participants group_id="P15" count="2"/>
                <participants group_id="P16" count="4"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="3"/>
                <participants group_id="P11" count="3"/>
                <participants group_id="P12" count="4"/>
                <participants group_id="P13" count="8"/>
                <participants group_id="P14" count="18"/>
                <participants group_id="P15" count="8"/>
                <participants group_id="P16" count="5"/>
                <participants group_id="P17" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="2"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="1"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="1"/>
                <participants group_id="P14" count="1"/>
                <participants group_id="P15" count="2"/>
                <participants group_id="P16" count="1"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progressive Disease</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="3"/>
                <participants group_id="P13" count="5"/>
                <participants group_id="P14" count="13"/>
                <participants group_id="P15" count="6"/>
                <participants group_id="P16" count="2"/>
                <participants group_id="P17" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrew Consent</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="1"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="1"/>
                <participants group_id="P14" count="1"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor's Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Completed Treatment Per Protocol at the Time</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="1"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant Went on to Have an Allograft</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="1"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The Full Analysis Set included all the participants who received at least 1 dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Tirabrutinib 20 mg Once Daily (CLL)</title>
          <description>Participants with relapsed/refractory CLL received tirabrutinib 20 mg once daily.</description>
        </group>
        <group group_id="B2">
          <title>Tirabrutinib 40 mg Once Daily (CLL)</title>
          <description>Participants with relapsed/refractory CLL received tirabrutinib 40 mg once daily.</description>
        </group>
        <group group_id="B3">
          <title>Tirabrutinib 80 mg Once Daily (CLL)</title>
          <description>Participants with relapsed/refractory CLL received tirabrutinib 80 mg once daily.</description>
        </group>
        <group group_id="B4">
          <title>Tirabrutinib 160 mg Once Daily (CLL)</title>
          <description>Participants with relapsed/refractory CLL received tirabrutinib 160 mg once daily.</description>
        </group>
        <group group_id="B5">
          <title>Tirabrutinib 320 mg Once Daily (CLL)</title>
          <description>Participants with relapsed/refractory CLL received tirabrutinib 320 mg once daily.</description>
        </group>
        <group group_id="B6">
          <title>Tirabrutinib 400 mg Once Daily (CLL)</title>
          <description>Participants with relapsed/refractory CLL received tirabrutinib 400 mg once daily.</description>
        </group>
        <group group_id="B7">
          <title>Tirabrutinib 500 mg Once Daily (CLL)</title>
          <description>Participants with relapsed/refractory CLL received tirabrutinib 500 mg once daily.</description>
        </group>
        <group group_id="B8">
          <title>Tirabrutinib 600 mg Once Daily (CLL)</title>
          <description>Participants with relapsed/refractory CLL received tirabrutinib 600 mg once daily.</description>
        </group>
        <group group_id="B9">
          <title>Tirabrutinib 300 mg Twice Daily (CLL)</title>
          <description>Participants with relapsed/refractory CLL received tirabrutinib 300 mg twice daily.</description>
        </group>
        <group group_id="B10">
          <title>Tirabrutinib 20 mg Once Daily (NHL)</title>
          <description>Participants with relapsed/refractory NHL received tirabrutinib 20 mg once daily.</description>
        </group>
        <group group_id="B11">
          <title>Tirabrutinib 40 mg Once Daily (NHL)</title>
          <description>Participants with relapsed/refractory NHL received tirabrutinib 40 mg once daily.</description>
        </group>
        <group group_id="B12">
          <title>Tirabrutinib 80 mg Once Daily (NHL)</title>
          <description>Participants with relapsed/refractory NHL received tirabrutinib 80 mg once daily.</description>
        </group>
        <group group_id="B13">
          <title>Tirabrutinib 160 mg Once Daily (NHL)</title>
          <description>Participants with relapsed/refractory NHL received tirabrutinib 160 mg once daily.</description>
        </group>
        <group group_id="B14">
          <title>Tirabrutinib 320 mg Once Daily (NHL)</title>
          <description>Participants with relapsed/refractory NHL received tirabrutinib 320 mg once daily.</description>
        </group>
        <group group_id="B15">
          <title>Tirabrutinib 480 mg Once Daily (NHL)</title>
          <description>Participants with relapsed/refractory NHL received tirabrutinib 480 mg once daily.</description>
        </group>
        <group group_id="B16">
          <title>Tirabrutinib 600 mg Once Daily (NHL)</title>
          <description>Participants with relapsed/refractory NHL received tirabrutinib 600 mg once daily.</description>
        </group>
        <group group_id="B17">
          <title>Tirabrutinib 240 mg Twice Daily (NHL)</title>
          <description>Participants with relapsed/refractory NHL received tirabrutinib 240 mg twice daily.</description>
        </group>
        <group group_id="B18">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="3"/>
            <count group_id="B5" value="3"/>
            <count group_id="B6" value="3"/>
            <count group_id="B7" value="3"/>
            <count group_id="B8" value="3"/>
            <count group_id="B9" value="3"/>
            <count group_id="B10" value="3"/>
            <count group_id="B11" value="3"/>
            <count group_id="B12" value="5"/>
            <count group_id="B13" value="8"/>
            <count group_id="B14" value="21"/>
            <count group_id="B15" value="10"/>
            <count group_id="B16" value="9"/>
            <count group_id="B17" value="3"/>
            <count group_id="B18" value="90"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt; 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="2"/>
                    <measurement group_id="B12" value="3"/>
                    <measurement group_id="B13" value="7"/>
                    <measurement group_id="B14" value="7"/>
                    <measurement group_id="B15" value="6"/>
                    <measurement group_id="B16" value="2"/>
                    <measurement group_id="B17" value="1"/>
                    <measurement group_id="B18" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥ 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="3"/>
                    <measurement group_id="B10" value="3"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="2"/>
                    <measurement group_id="B13" value="1"/>
                    <measurement group_id="B14" value="14"/>
                    <measurement group_id="B15" value="4"/>
                    <measurement group_id="B16" value="7"/>
                    <measurement group_id="B17" value="2"/>
                    <measurement group_id="B18" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="1"/>
                    <measurement group_id="B14" value="8"/>
                    <measurement group_id="B15" value="3"/>
                    <measurement group_id="B16" value="3"/>
                    <measurement group_id="B17" value="2"/>
                    <measurement group_id="B18" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="2"/>
                    <measurement group_id="B12" value="5"/>
                    <measurement group_id="B13" value="7"/>
                    <measurement group_id="B14" value="13"/>
                    <measurement group_id="B15" value="7"/>
                    <measurement group_id="B16" value="6"/>
                    <measurement group_id="B17" value="1"/>
                    <measurement group_id="B18" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="3"/>
                    <measurement group_id="B11" value="3"/>
                    <measurement group_id="B12" value="3"/>
                    <measurement group_id="B13" value="7"/>
                    <measurement group_id="B14" value="16"/>
                    <measurement group_id="B15" value="9"/>
                    <measurement group_id="B16" value="8"/>
                    <measurement group_id="B17" value="3"/>
                    <measurement group_id="B18" value="75"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="1"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="1"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="2"/>
                    <measurement group_id="B13" value="1"/>
                    <measurement group_id="B14" value="4"/>
                    <measurement group_id="B15" value="1"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Experiencing Dose-Limiting Toxicities</title>
        <description>Dose Limiting Toxicities (DLT) were defined as follows:&#xD;
All Common Terminology Criteria (CTC) Grade 4 tirabrutinib related adverse events&#xD;
All CTC Grade 3 tirabrutinib related adverse events, with the exception of the following:&#xD;
CTC Grade 3 lymphocytosis considered an expected outcome of therapy&#xD;
Any toxicity which in the opinion of the Investigator is attributed to a participant's underlying disease was not considered a DLT.</description>
        <time_frame>Day 1 through Day 28</time_frame>
        <population>The Safety Analysis Set included all the participants who received at least 1 dose of study drug. Per planned analysis, data for DLTs were summarized by dose level received by participants with NHL and CLL.</population>
        <group_list>
          <group group_id="O1">
            <title>Tirabrutinib 20 mg Once Daily (CLL)</title>
            <description>Participants with relapsed/refractory CLL received tirabrutinib 20 mg once daily.</description>
          </group>
          <group group_id="O2">
            <title>Tirabrutinib 40 mg Once Daily (CLL)</title>
            <description>Participants with relapsed/refractory CLL received tirabrutinib 40 mg once daily.</description>
          </group>
          <group group_id="O3">
            <title>Tirabrutinib 80 mg Once Daily (CLL)</title>
            <description>Participants with relapsed/refractory CLL received tirabrutinib 80 mg once daily.</description>
          </group>
          <group group_id="O4">
            <title>Tirabrutinib 160 mg Once Daily (CLL)</title>
            <description>Participants with relapsed/refractory CLL received tirabrutinib 160 mg once daily.</description>
          </group>
          <group group_id="O5">
            <title>Tirabrutinib 320 mg Once Daily (CLL)</title>
            <description>Participants with relapsed/refractory CLL received tirabrutinib 320 mg once daily.</description>
          </group>
          <group group_id="O6">
            <title>Tirabrutinib 400 mg Once Daily (CLL)</title>
            <description>Participants with relapsed/refractory CLL received tirabrutinib 400 mg once daily.</description>
          </group>
          <group group_id="O7">
            <title>Tirabrutinib 500 mg Once Daily (CLL)</title>
            <description>Participants with relapsed/refractory CLL received tirabrutinib 500 mg once daily.</description>
          </group>
          <group group_id="O8">
            <title>Tirabrutinib 600 mg Once Daily (CLL)</title>
            <description>Participants with relapsed/refractory CLL received tirabrutinib 600 mg once daily.</description>
          </group>
          <group group_id="O9">
            <title>Tirabrutinib 300 mg Twice Daily (CLL)</title>
            <description>Participants with relapsed/refractory CLL received tirabrutinib 300 mg twice daily.</description>
          </group>
          <group group_id="O10">
            <title>Tirabrutinib 20 mg Once Daily (NHL)</title>
            <description>Participants with relapsed/refractory NHL received tirabrutinib 20 mg once daily.</description>
          </group>
          <group group_id="O11">
            <title>Tirabrutinib 40 mg Once Daily (NHL)</title>
            <description>Participants with relapsed/refractory NHL received tirabrutinib 40 mg once daily.</description>
          </group>
          <group group_id="O12">
            <title>Tirabrutinib 80 mg Once Daily (NHL)</title>
            <description>Participants with relapsed/refractory NHL received tirabrutinib 80 mg once daily.</description>
          </group>
          <group group_id="O13">
            <title>Tirabrutinib 160 mg Once Daily (NHL)</title>
            <description>Participants with relapsed/refractory NHL received tirabrutinib 160 mg once daily.</description>
          </group>
          <group group_id="O14">
            <title>Tirabrutinib 320 mg Once Daily (NHL)</title>
            <description>Participants with relapsed/refractory NHL received tirabrutinib 320 mg once daily.</description>
          </group>
          <group group_id="O15">
            <title>Tirabrutinib 480 mg Once Daily (NHL)</title>
            <description>Participants with relapsed/refractory NHL received tirabrutinib 480 mg once daily.</description>
          </group>
          <group group_id="O16">
            <title>Tirabrutinib 600 mg Once Daily (NHL)</title>
            <description>Participants with relapsed/refractory NHL received tirabrutinib 600 mg once daily.</description>
          </group>
          <group group_id="O17">
            <title>Tirabrutinib 240 mg Twice Daily (NHL)</title>
            <description>Participants with relapsed/refractory NHL received tirabrutinib 240 mg twice daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Experiencing Dose-Limiting Toxicities</title>
          <description>Dose Limiting Toxicities (DLT) were defined as follows:&#xD;
All Common Terminology Criteria (CTC) Grade 4 tirabrutinib related adverse events&#xD;
All CTC Grade 3 tirabrutinib related adverse events, with the exception of the following:&#xD;
CTC Grade 3 lymphocytosis considered an expected outcome of therapy&#xD;
Any toxicity which in the opinion of the Investigator is attributed to a participant's underlying disease was not considered a DLT.</description>
          <population>The Safety Analysis Set included all the participants who received at least 1 dose of study drug. Per planned analysis, data for DLTs were summarized by dose level received by participants with NHL and CLL.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="3"/>
                <count group_id="O11" value="3"/>
                <count group_id="O12" value="5"/>
                <count group_id="O13" value="8"/>
                <count group_id="O14" value="21"/>
                <count group_id="O15" value="10"/>
                <count group_id="O16" value="9"/>
                <count group_id="O17" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="33.3"/>
                    <measurement group_id="O7" value="0.0"/>
                    <measurement group_id="O8" value="0.0"/>
                    <measurement group_id="O9" value="33.3"/>
                    <measurement group_id="O10" value="0.0"/>
                    <measurement group_id="O11" value="0.0"/>
                    <measurement group_id="O12" value="0.0"/>
                    <measurement group_id="O13" value="0.0"/>
                    <measurement group_id="O14" value="4.8"/>
                    <measurement group_id="O15" value="10.0"/>
                    <measurement group_id="O16" value="22.2"/>
                    <measurement group_id="O17" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Response Rate</title>
        <description>Overall response rate (ORR) was defined as the percentage of participants who achieve a best overall response of complete remission (CR, unconfirmed complete response (CRu), complete response with incomplete marrow recovery (CRi)) or partial remission (PR, nodal PR) during study as assessed by the investigator.&#xD;
ORR assessment was defined per following standardized criteria:&#xD;
NHL: Cheson, 1999&#xD;
CLL: International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008</description>
        <time_frame>Up to Cycle 37 (28 days for each cycle) plus 6-month intervals thereafter until disease progression (maximum: up to 39 months)</time_frame>
        <population>The Full Analysis Set included all the participants who received at least 1 dose of study drug. Per planned analysis, data for overall response rate were summarized by overall CLL group and NHL subgroup.</population>
        <group_list>
          <group group_id="O1">
            <title>Chronic Lymphocytic Leukaemia</title>
            <description>Participants with relapsed/refractory CLL received tirabrutinib until disease progression or until the participant entered into a possible future tirabrutinib study.</description>
          </group>
          <group group_id="O2">
            <title>NHL Subtype FL</title>
            <description>Participants with NHL subtype follicular lymphoma (FL) received tirabrutinib until disease progression or until the participant entered into a possible future tirabrutinib study.</description>
          </group>
          <group group_id="O3">
            <title>NHL Subtype SLL</title>
            <description>Participants with NHL subtype small lymphocytic lymphoma (SLL) received tirabrutinib until disease progression or until the participant entered into a possible future tirabrutinib study.</description>
          </group>
          <group group_id="O4">
            <title>NHL Subtype WM</title>
            <description>Participants with NHL subtype Waldenstrom macroglobulinemia (WM) received tirabrutinib until disease progression or until the participant entered into a possible future tirabrutinib study.</description>
          </group>
          <group group_id="O5">
            <title>NHL Subtype MZL</title>
            <description>Participants with NHL subtype marginal zone lymphoma (MZL) received tirabrutinib until disease progression or until the participant entered into a possible future tirabrutinib study.</description>
          </group>
          <group group_id="O6">
            <title>NHL Subtype DLBCL</title>
            <description>Participants with NHL subtype diffuse large B-cell lymphoma (DLBCL) received tirabrutinib until disease progression or until the participant entered into a possible future tirabrutinib study.</description>
          </group>
          <group group_id="O7">
            <title>NHL Subtype MCL</title>
            <description>Participants with NHL subtype mantle cell lymphoma (MCL) received tirabrutinib until disease progression or until the participant entered into a possible future tirabrutinib study.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate</title>
          <description>Overall response rate (ORR) was defined as the percentage of participants who achieve a best overall response of complete remission (CR, unconfirmed complete response (CRu), complete response with incomplete marrow recovery (CRi)) or partial remission (PR, nodal PR) during study as assessed by the investigator.&#xD;
ORR assessment was defined per following standardized criteria:&#xD;
NHL: Cheson, 1999&#xD;
CLL: International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008</description>
          <population>The Full Analysis Set included all the participants who received at least 1 dose of study drug. Per planned analysis, data for overall response rate were summarized by overall CLL group and NHL subgroup.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="2"/>
                <count group_id="O6" value="35"/>
                <count group_id="O7" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.7"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="33.3"/>
                    <measurement group_id="O5" value="50.0"/>
                    <measurement group_id="O6" value="31.4"/>
                    <measurement group_id="O7" value="68.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic (PK) Parameter: Cmax of Tirabrutinib</title>
        <description>Cmax is defined as the maximum concentration of drug.</description>
        <time_frame>Pre-dose, then 30 minutes, 1, 2, 3, 4, 6, 8, 12 hours post-dose at Cycle 1, Day 28</time_frame>
        <population>Participants in the PK Analysis Set (all participants who received at least 1 dose of study drug and had at least 1 nonmissing postdose concentration value for the corresponding analyte in plasma) with available data were analyzed. Per planned analysis, data for PK parameters were summarized by dose cohorts.</population>
        <group_list>
          <group group_id="O1">
            <title>Tirabrutinib 20 mg Once Daily (CLL or NHL)</title>
            <description>Participants with relapsed/refractory CLL or NHL received tirabrutinib 20 mg once daily.</description>
          </group>
          <group group_id="O2">
            <title>Tirabrutinib 40 mg Once Daily (CLL or NHL)</title>
            <description>Participants with relapsed/refractory CLL or NHL received tirabrutinib 40 mg once daily.</description>
          </group>
          <group group_id="O3">
            <title>Tirabrutinib 80 mg Once Daily (CLL or NHL)</title>
            <description>Participants with relapsed/refractory CLL or NHL received tirabrutinib 80 mg once daily.</description>
          </group>
          <group group_id="O4">
            <title>Tirabrutinib 160 mg Once Daily (CLL or NHL)</title>
            <description>Participants with relapsed/refractory CLL or NHL received tirabrutinib 160 mg once daily.</description>
          </group>
          <group group_id="O5">
            <title>Tirabrutinib 320 mg Once Daily (CLL or NHL)</title>
            <description>Participants with relapsed/refractory CLL or NHL received tirabrutinib 320 mg once daily.</description>
          </group>
          <group group_id="O6">
            <title>Tirabrutinib 400 mg Once Daily (CLL)</title>
            <description>Participants with relapsed/refractory CLL received tirabrutinib 400 mg once daily.</description>
          </group>
          <group group_id="O7">
            <title>Tirabrutinib 480 mg Once Daily (NHL)</title>
            <description>Participants with relapsed/refractory NHL received tirabrutinib 480 mg once daily.</description>
          </group>
          <group group_id="O8">
            <title>Tirabrutinib 500 mg Once Daily (CLL)</title>
            <description>Participants with relapsed/refractory CLL received tirabrutinib 500 mg once daily.</description>
          </group>
          <group group_id="O9">
            <title>Tirabrutinib 600 mg Once Daily (CLL or NHL)</title>
            <description>Participants with relapsed/refractory CLL or NHL received tirabrutinib 600 mg once daily.</description>
          </group>
          <group group_id="O10">
            <title>Tirabrutinib 240 mg Twice Daily (NHL)</title>
            <description>Participants with relapsed/refractory NHL received tirabrutinib 240 mg twice daily.</description>
          </group>
          <group group_id="O11">
            <title>Tirabrutinib 300 mg Twice Daily (CLL)</title>
            <description>Participants with relapsed/refractory CLL received tirabrutinib 300 mg twice daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic (PK) Parameter: Cmax of Tirabrutinib</title>
          <description>Cmax is defined as the maximum concentration of drug.</description>
          <population>Participants in the PK Analysis Set (all participants who received at least 1 dose of study drug and had at least 1 nonmissing postdose concentration value for the corresponding analyte in plasma) with available data were analyzed. Per planned analysis, data for PK parameters were summarized by dose cohorts.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="17"/>
                <count group_id="O6" value="2"/>
                <count group_id="O7" value="7"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="3"/>
                <count group_id="O11" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.4" spread="18.26"/>
                    <measurement group_id="O2" value="164.5" spread="47.22"/>
                    <measurement group_id="O3" value="241" spread="90.68"/>
                    <measurement group_id="O4" value="539.6" spread="141.58"/>
                    <measurement group_id="O5" value="1181.6" spread="380.39"/>
                    <measurement group_id="O6" value="826.5" spread="499.92"/>
                    <measurement group_id="O7" value="1240.3" spread="516.99"/>
                    <measurement group_id="O8" value="1230" spread="285.83"/>
                    <measurement group_id="O9" value="1265.2" spread="486.21"/>
                    <measurement group_id="O10" value="704.3" spread="254.51"/>
                    <measurement group_id="O11" value="674.3" spread="93.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK Parameter: AUCtau of Tirabrutinib</title>
        <description>AUCtau is defined as concentration of drug over dosing interval.</description>
        <time_frame>Pre-dose, then 30 minutes, 1, 2, 3, 4, 6, 8, 12 hours post-dose at Cycle 1, Day 28</time_frame>
        <population>Participants in the PK Analysis Set with available data were analyzed. Per planned analysis, data for PK parameters were summarized by dose cohorts.</population>
        <group_list>
          <group group_id="O1">
            <title>Tirabrutinib 20 mg Once Daily (CLL or NHL)</title>
            <description>Participants with relapsed/refractory CLL or NHL received tirabrutinib 20 mg once daily.</description>
          </group>
          <group group_id="O2">
            <title>Tirabrutinib 40 mg Once Daily (CLL or NHL)</title>
            <description>Participants with relapsed/refractory CLL or NHL received tirabrutinib 40 mg once daily.</description>
          </group>
          <group group_id="O3">
            <title>Tirabrutinib 80 mg Once Daily (CLL or NHL)</title>
            <description>Participants with relapsed/refractory CLL or NHL received tirabrutinib 80 mg once daily.</description>
          </group>
          <group group_id="O4">
            <title>Tirabrutinib 160 mg Once Daily (CLL or NHL)</title>
            <description>Participants with relapsed/refractory CLL or NHL received tirabrutinib 160 mg once daily.</description>
          </group>
          <group group_id="O5">
            <title>Tirabrutinib 320 mg Once Daily (CLL or NHL)</title>
            <description>Participants with relapsed/refractory CLL or NHL received tirabrutinib 320 mg once daily.</description>
          </group>
          <group group_id="O6">
            <title>Tirabrutinib 400 mg Once Daily (CLL)</title>
            <description>Participants with relapsed/refractory CLL received tirabrutinib 400 mg once daily.</description>
          </group>
          <group group_id="O7">
            <title>Tirabrutinib 480 mg Once Daily (NHL)</title>
            <description>Participants with relapsed/refractory NHL received tirabrutinib 480 mg once daily.</description>
          </group>
          <group group_id="O8">
            <title>Tirabrutinib 500 mg Once Daily (CLL)</title>
            <description>Participants with relapsed/refractory CLL received tirabrutinib 500 mg once daily.</description>
          </group>
          <group group_id="O9">
            <title>Tirabrutinib 600 mg Once Daily (CLL or NHL)</title>
            <description>Participants with relapsed/refractory CLL or NHL received tirabrutinib 600 mg once daily.</description>
          </group>
          <group group_id="O10">
            <title>Tirabrutinib 240 mg Twice Daily (NHL)</title>
            <description>Participants with relapsed/refractory NHL received tirabrutinib 240 mg twice daily.</description>
          </group>
          <group group_id="O11">
            <title>Tirabrutinib 300 mg Twice Daily (CLL)</title>
            <description>Participants with relapsed/refractory CLL received tirabrutinib 300 mg twice daily.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Parameter: AUCtau of Tirabrutinib</title>
          <description>AUCtau is defined as concentration of drug over dosing interval.</description>
          <population>Participants in the PK Analysis Set with available data were analyzed. Per planned analysis, data for PK parameters were summarized by dose cohorts.</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="17"/>
                <count group_id="O6" value="2"/>
                <count group_id="O7" value="7"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="5"/>
                <count group_id="O10" value="3"/>
                <count group_id="O11" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="306.4" spread="74.92"/>
                    <measurement group_id="O2" value="660.1" spread="310.95"/>
                    <measurement group_id="O3" value="762" spread="374.94"/>
                    <measurement group_id="O4" value="2681.8" spread="1055.17"/>
                    <measurement group_id="O5" value="5664.8" spread="1829.07"/>
                    <measurement group_id="O6" value="5259.5" spread="3166.57"/>
                    <measurement group_id="O7" value="7999.8" spread="2006.19"/>
                    <measurement group_id="O8" value="6766.9" spread="1025.64"/>
                    <measurement group_id="O9" value="8442.2" spread="2499.22"/>
                    <measurement group_id="O10" value="3415.5" spread="1296.47"/>
                    <measurement group_id="O11" value="3297.2" spread="1330"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events: First dose date up to the last dose date plus 30 days (maximum: 36 months); All-Cause Mortality: First dose date up to 39 months</time_frame>
      <desc>The Safety Analysis Set included all the participants who received at least 1 dose of study drug. Per planned analysis, data were summarized by overall groups for NHL and CLL pooling all participants regardless of dose level received.</desc>
      <group_list>
        <group group_id="E1">
          <title>Chronic Lymphocytic Leukaemia</title>
          <description>Participants with relapsed/refractory CLL received tirabrutinib until disease progression or until the participant entered into a possible future tirabrutinib study.</description>
        </group>
        <group group_id="E2">
          <title>Non-Hodgkin's Lymphoma</title>
          <description>Participants with relapsed/refractory NHL received tirabrutinib until disease progression or until the participant entered into a possible future tirabrutinib study.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Lymphocytic infiltration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Spontaneous haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Excessive cerumen production</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Inguinal hernia strangulated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Oesophageal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Small intestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Ill-defined disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Campylobacter gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>H1n1 influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Hepatitis E</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Herpes zoster oticus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection fungal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Neutropenic infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Neutropenic sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Pneumocystis jirovecii pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Pneumonia pneumococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Cardiac function disturbance postoperative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colorectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of lung</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Myeloma cast nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Purpura</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Eye haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypogammaglobulinaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Eye infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Sinobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Traumatic haematoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Joint stiffness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Skin papilloma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Dysaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Prostatomegaly</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Catarrh</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Rales</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Actinic keratosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Macule</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Purpura</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Rash macular</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Swelling face</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:&#xD;
The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or&#xD;
The study has been completed at all study sites for at least 2 years</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gilead Clinical Study Information Center</name_or_title>
      <organization>Gilead Sciences</organization>
      <phone>1-833-445-3230 (GILEAD-0)</phone>
      <email>GileadClinicalTrials@gilead.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

